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Abstract
We postulate that an orchestrated network composed of various vasodilatory systems participates
in the systemic and local hemodynamic adaptations in pregnancy. The temporal patterns of increase
in the circulating and urinary levels of five vasodilator factors/systems, prostacyclin, nitric oxide,
kallikrein, angiotensin-(1–7) and VEGF, in normal pregnant women and animals, as well as the
changes observed in preeclamptic pregnancies support their functional role in maintaining
normotension by opposing the vasoconstrictor systems. In addition, the expression of these
vasodilators in the different trophoblastic subtypes in various species supports their role in the
transformation of the uterine arteries. Moreover, their expression in the fetal endothelium and in
the syncytiotrophoblast in humans, rats and guinea-pigs, favour their participation in maintaining the
uteroplacental circulation. The findings that sustain the functional associations of the various
vasodilators, and their participation by endocrine, paracrine and autocrine regulation of the
systemic and local vasoactive changes of pregnancy are abundant and compelling. However, further
elucidation of the role of the various players is hampered by methodological problems. Among
these difficulties is the complexity of the interactions between the different factors, the likelihood
that experimental alterations induced in one system may be compensated by the other players of
the network, and the possibility that data obtained by manipulating single factors in vitro or in
animal studies may be difficult to translate to the human. In addition, the impossibility of sampling
the uteroplacental interface along normal pregnancy precludes obtaining longitudinal profiles of the
various players. Nevertheless, the possibility of improving maternal blood pressure regulation,
trophoblast invasion and uteroplacental flow by enhancing vasodilation (e.g. L-arginine, NO donors,
VEGF transfection) deserves unravelling the intricate association of vasoactive factors and the
systemic and local adaptations to pregnancy.
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Background
In primates adequate development of the embryo, and
later of the fetus, depends on a successful hemomonocho-
rial placentation. This is achieved firstly, by the adaptation
of the uterine vessels to pregnancy, with colonization of
the uteroplacental arteries by the extravillous trophoblast
cells[1,2], and secondly, by the creation of the fetoplacen-
tal vascular network of the placental villi from haeman-
gioblastic precursor cells[3,4]. In addition, the systemic
maternal circulation adapts to favor uteroplacental per-
fusion, through increases in plasma volume and cardiac
output[5,6].
In this setting the normotension of approximately 90% of
human pregnancies, the blood pressure decrement of the
second trimester[7], and the reductions in peripheral
resistance[8] and sensitivity to angiotensin II[9] are hard
to understand. With the belief that an orchestrated con-
junction of the various vasodilatory systems participates
in the systemic and local hemodynamic adaptations in
pregnancy, we have strived to understand their localiza-
tion, modulation, and potential role. In the following
review, a brief description of the main vasodilator sys-
tems/agents and their interactions is given, followed by
their systemic uterine and placental expression that sup-
port their participation in normal pregnancy.
General aspects of vasodilator systems
Prostanoids
Arachidonic acid is an unsaturated constituent of the
phospholipid domain of cell membranes. It is mobilized
by phospholipases, especially cytoplasmatic phospholi-
pase A2, and is metabolized by constitutive cyclooxygen-
ase (COX-1) and inducible COX-2 into prostaglandins
and related compounds, by lipooxygenase into leukot-
rienes and by p450 into epoxieicosanoid acids[10]. Pros-
taglandin PGH2  is later converted into a variety of
eicosanoids by different enzymes. The vasodilators PGE2
and prostacyclin (PGI2) by PGH-PGE isomerase and pros-
tacyclin synthase respectively. The vasoconstrictors PGF2a
and thromboxane (TXA2) by PGF2a reductase and throm-
bane synthase respectively. (Figure 1). The distribution of
the enzymes, and hence of the derived prostanoids, is cell-
specific.
PGI2 is the major vasodilator within the prostaglandin
cascade and is synthesized predominantly by the endothe-
lium[11]. Its main effects are mediated either directly, or
by opposing the vasoconstrictor and proaggregating effect
of platelet-derived TXA2. In this review we will focus on
PGI2 and TXA2, as these are the best studied prostanoids in
pregnancy.
Nitric oxide
Nitric oxide, a potent vasodilator, derives from the oxida-
tion of L-arginine into NO and L-citrulline by nitric oxide
synthase (NOS)[12]. There are three cognate forms of
NOS, neuronal NOS (nNOS, brain NOS or type I NOS);
inducible NOS (iNOS or type II NOS) and endothelial
NOS (eNOS or type III) (Figure 2). Endothelial and neu-
ronal NOS are constitutive enzymes, are dependent on
Ca+2 and calmodulin, and generate small amounts of NO
for vasodilation, maintenance of vascular tone, antiplate-
let aggregation and neurotransmission, respectively. In
contrast, iNOS is an inflammation-inducible Ca+2 inde-
pendent enzyme that liberates great amounts of NO.
Whether NO plays a protective[13], or a cytotoxic role[14]
depends on the magnitude and duration of its synthesis.
Kallikrein-kinin system
This endogenous cascade includes a couple of serine pro-
teases, namely tissue and plasma kallikrein, that generate
kallidin and bradykinin from precursors, low and high
molecular weight kininogens.
The effects of kinins, both kallidin and bradykinin are
mediated by two types of receptors, type 1 or B1R and type
2 or B2R, acting by way of the G protein coupled receptor
(GPCR). By activating the B2R, kinins induce vasodila-
tion, increase vascular permeability and antiplatelet aggre-
gation, both directly or by stimulating the synthesis of
nitric oxide (NO) and PGI2. On the other hand, acting on
the B1R, kinins induce pain and participate in mitogene-
sis and angiogenesis (Figure 3). [15]
Vasodilator components of the renin-angiotensin system
Recent findings have added a vasodilator arm to the renin-
angiotensin system (RAS), which until recently was only
seen as a classical vasoconstrictor system[16,17]. The
three components of this vasodilatory arm are angi-
otensin-(1–7) (Ang-(1–7)) as the vasoactive peptide, Mas,
as the respective receptor, and ACE2 (angiotensin convert-
ing enzyme 2) as the enzyme linking Ang-(1–7) to the
RAS. There are three routes for the conversion into Ang-
(1–7). Firstly, it is converted from Ang II (aminoacids 1–
8) by cleaving off one amino acid, mediated by ACE2, by
prolyl endopeptidase (PEP), or by the carboxypeptidase
(CPB). As an alternative, Ang-(1–7) can be directly con-
verted from Ang I (aminoacids 1–10) by cleaving off three
aminoacids by neutral endopeptidase (NEP). Finally con-
version from Ang I into Ang-(1–7) may take place in two
steps, the first mediated by ACE2, which generates Ang
(1–9), which is then converted to Ang-(1–7) by ACE and
NEP (Figure 4).
Ang-(1–7) binding to the Mas receptor causes vasodila-
tion and inhibition of smooth muscle growth, collagen
production, angiogenesis and thrombosis. In addition,Reproductive Biology and Endocrinology 2009, 7:79 http://www.rbej.com/content/7/1/79
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the vasodilatory effect of Ang-(1–7) could be partly
explained by stimulating NO or PGI2, by potentiating
bradykinin via the Mas receptor [18-21], and by compet-
ing with Ang I for ACE[22]
In contrast to the classical effects of Ang II mediated by the
AT1 receptor (vasoconstriction, cell proliferation, fibrosis,
angiogenesis), Ang II binding to the AT2 receptor displays
vasodilatory, antiproliferative, antifibrotic and antiang-
iogenic effects by activating eNOS and kinins [23-25].
VEGF-A as a vasodilator: Though there are four endog-
enous isoforms of vascular endothelial growth factor
(VEGF), we refer to VEGF exclusively to VEGF-A. VEGF
induces vascular permeability, cell migration and protease
production by endothelial cells, all of which are critical
components of the angiogenic process, the main function
attributed to VEGF[26,27]. In placentation, the modula-
tion of vascular development and remodeling, growth
and differentiation by VEGF is shared by placental growth
factor (PlGF) and angiopoietins 1 and 2[3,28]; all three of
them yield different, but overlapping spectra of activities.
In addition VEGF is also an endothelium-dependent
vasodilator[29], exerting its effect through NO[30] and
PGI2[31].
VEGF binds to tyrosine kinase receptors (TKRs), of which
VEGFR-1 (tyrosine kinase-1 type fms [Flt-1]), modulated
by VEGFR-2 (Flk-1/kinase domain [KDR]), exerts a
vasodilatory effect [26,32]. (Figure 5)
The cognate interactions between the different vasodilator
factors are summarized in Figure 6. It is worth mentioning
that, as depicted in Figures 1 to 5, these factors have a mul-
Synthesis of prostanoids and their respective vasodilator and vasoconstrictor actions Figure 1
Synthesis of prostanoids and their respective vasodilator and vasoconstrictor actions.
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tiplicity of roles which probably facilitate invasion, pla-
cental development and the preservation of an
antiaggregated surface of the intervillous space.
Association of the vasodilator systems to the maternal 
systemic adaptations to pregnancy
Prostanoids were the first endogenous vasoactive factors
studied in pregnancy[33,34], and rapidly prostacyclin and
thromboxane became the main protagonists of this sys-
tem [34-36]. For more than 20 years there has been evi-
dence that in normal pregnancy urinary metabolites of
prostacyclin increase progressively, attaining up to 5-fold
rise during the last month of pregnancy. As this elevation
is not associated to changes in the urinary excretion of
thromboxane B2, the balance favors the vasodilator versus
the vasoconstrictor balance of this vasoactive pair [37]. In
women with severe preeclampsia the urinary excretion of
the prostacyclin metabolites is lower than in normoten-
sive women during the last trimester of pregnancy, while
thromboxane levels are unchanged, shifting the balance
to the debit of the vasoconstrictor and procoagulant TXA2.
This imbalance, now attributed to an increment in lipid
peroxidation and a decrement of scavengers[38], is
thought to contribute to the main features of preeclamp-
sia, including hypertension, platelet aggregation, and
reduced uteroplacental blood flow. A large scale prospec-
tive study shows that the preeclamptic women have lower
urinary excretion of prostacyclin metabolites as early as
weeks 13 to 16, which yielded a consistently higher
thromboxane/PGI2 ratio starting at week 16; however,
higher TXA2 levels observed after 21 weeks have been
interpreted as a secondary event[39].
Following the discovery that prostacyclin and thrombox-
ane levels are disturbed in the maternal circulation in
preeclampsia, a number of centers have performed clini-
cal trials with low dose aspirin, believing that treatment
with cyclooxygenase inhibitors could prevent or amelio-
rate the disorder by reducing platelet TXA2 production
while sparing endothelial PGI2 synthesis. Reduction in the
incidence of preeclampsia in large scale trials are modest
(e.g. 12% in CLASP[40]), suggesting that there is more to
preeclampsia than an increment of thromboxane produc-
tion.
Nitric oxide biosynthesis is increased in pregnant rats, as
evidenced by increased plasma and urinary levels of
nitrate, and of urinary cGMP[41,42]. In addition, the
blockade of NO synthesis in animal models induces
marked preeclampsia-like effects[43,44]. Changes of
nitrite/nitrate (NOx) levels in different conditions of
human pregnancy have been discordant. The discrepan-
cies have been partly attributed to the dependency
between dietary intake and plasma and urinary levels; this
can be circumvented by a reduction or and control of die-
tary intake[45]. Sampling under a reduced nitrite/nitrate
(NOx) diet has demonstrated a decrease of plasma NOx in
the first trimester. This is followed by a later rise to values
in nonpregnant women, unchanged urinary NOx, and an
increase of urinary cGMP (the second messenger of NO)
in the second and third trimester. In preeclampsia plasma
NOx and urinary cGMP are similar to normal pregnancy,
while urinary NOx is reduced [45-47], so that unequivocal
demonstration of a reduced NO synthesis is absent, prob-
ably due to lack of systemic or urinary translation of
hemodynamically relevant NO production. Nevertheless,
elevation of the plasma dimethylarginine (ADMA), an
endogenous inhibitor of NOS, in the second trimester is
associated with endothelial dysfunction, impaired uterine
artery Doppler and the subsequent development of preec-
lampsia[48].
Valdés et al [50] originally hypothesized that the kal-
likrein-kinin system in pregnancy could represent a coun-
terregulatory system to the renin-angiotensin system.
However, neither the data obtained in the rat or in
humans support the view of a contemporary counterregu-
L-arginine-nitric oxide (NO) pathway indicating the effects of  NO according to its generating enzymes and tissue levels Figure 2
L-arginine-nitric oxide (NO) pathway indicating the 
effects of NO according to its generating enzymes 
and tissue levels.
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lation. In rats, urinary kallikrein – as a reflection of renal
synthesis – rises from gestational day 4 onwards, while
plasma renin activity is increased only at day 20, of a 21
to 22 gestation period[49]. In normal pregnant women a
rise in urinary kallikrein precedes that of the vasoconstric-
tors, reaching its maximum between 8 to 12 weeks[50].
Reduced urinary kallikrein levels have been observed in
hypertensive pregnancies[51,52], and lower levels predict
the preeclamptic syndrome as early as 16 weeks of preg-
nancy[53].
In normal pregnancy several findings support a predomi-
nance of the vasodilator effects of the renin-angiotensin-
system, as opposed to an activation of its pressor actions
in preeclampsia. Plasma renin activity (PRA) rises progres-
sively along pregnancy, to attain levels 10-fold greater
than non-gestational values[7]. In preeclampsia PRA,
plasma renin concentration and plasma Ang II are
reduced compared to normal pregnancy[52]. Although
plasma Ang II concentrations are reduced, women who
will develop preeclampsia show a heightened pressor
response to Ang II infusion weeks in advance to the clini-
cal manifestation of the syndrome, while this response is
blunted in normotensive pregnant women[9]. Wallukat et
al. have detected an autoantibody in the serum of preec-
lamptic patients that binds to the AT1 receptor and has
agonist activity[54]. AT1-B2-receptor heterodimers, which
lead to increased Ang II-mediated signalling in smooth-
muscle, are highly increased on platelets and omental ves-
sels from preeclamptic patients compared with normo-
tensive pregnant women[55].
The generation of the recently described vasodilator Ang-
(1–7) is activated in normal human pregnancy, as demon-
strated by a progressive increase of urinary excretion of the
peptide starting at 12–14 weeks, and of plasma levels that
achieved in late gestation a 1.5-fold rise as compared to
non-pregnant values[56,57]. These elevations and the
reduced plasma levels of the peptide observed in preec-
lampsia[57] suggest that this vasodilator exerts a role in
Kallikrein-kinin system, and the effects of bradykinin according to the type of receptor Figure 3
Kallikrein-kinin system, and the effects of bradykinin according to the type of receptor.
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the maternal hemodynamic adaptation to pregnancy. In
contrast to human pregnancy, in the rat there is no signif-
icant change in plasma concentration of Ang (1–7) at the
19th day of pregnancy; however the renal concentration
and the urinary excretion increase 5 and 1.6-fold respec-
tively, as compared to virgin animals. In pregnant rats
Ang-(1–7) enhanced the dilation of mesenteric vessels,
while this effect was absent in the virgin females[58].
Total VEGF circulating levels increase approximately 30
days after embryo transfer, or at week 10 to 14 in sponta-
neous human pregnancies[59], and continue to rise until
An updated version of the renin-angiotensin system and the different functions of the active peptides through their receptors Figure 4
An updated version of the renin-angiotensin system and the different functions of the active peptides through 
their receptors.
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34–36 weeks to a 5-fold increase as compared to postpar-
tum values[60]. These findings suggest that apart from ful-
filling an angiogenic effect in reproductive tissues, VEGF
may be involved in maternal cardiovascular adaptation to
pregnancy. Moreover, a bipolar release of VEGF to the
maternal and fetal compartments has been documented
in dually perfused human term placental lobules, with
predominance of the release to the maternal side[61].
VEGF and plasma from women with preeclampsia induce
a concentration-dependent increase in prostacyclin pro-
duction in bovine endothelial cells, which is inhibited by
VEGF antibody[62]. However, binding of VEGF to cell
transmembrane receptors is reduced by a soluble circulat-
ing form of Flt-1 (sFlt-1), which is generated by alternative
splicing. In humans circulating levels of sFlt1 are low in
the non pregnant state, high in pregnancy, and extremely
high in preeclampsia, probably deriving from an ischemic
placenta[63,64]. In this condition most VEGF is bound to
the vast excess of circulating sFlt1, and free VEGF levels,
which represent active VEGF, are substantially lower than
those of total VEGF. In mice, transfection of the sFlt-1
gene generates a preeclampsia-like syndrome, with hyper-
tension, proteinuria, and glomerular endotheliosis, even
in the absence of pregnancy or a placenta[63].
The interferences with the activity of VEGF provide a
strong support to its vasodilatory role. Moreover, this role
is underscored by the effects of the enhancement of VEGF
on uteroplacental perfusion. Uterine arteries of pregnant
sheep overexpressing VEGF by adenoviral transfection tri-
pled their blood flow in vivo, and in vitro decreased the
response to phenylephrine while increasing bradykinin-
induced relaxation[65].
The studies described above support the concept that sev-
eral interrelated vasodilators are involved in the circula-
tory changes of pregnancy, probably providing partially
redundant systems. It is tempting to speculate that the
temporal profiles of the above mentioned vasodilator fac-
Different forms of VEGF, their receptors and their respective functions Figure 5
Different forms of VEGF, their receptors and their respective functions.
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tors constitute relay systems, which in the changing endo-
crine milieu of gestation provide constant vasodilation in
the mother. This assumption is supported by our finding
that the decline in kallikrein throughout pregnancy is
associated with a progressive rise of Ang-(1–7) (longitudi-
nal measurements from the urine of 10 normotensive
pregnancies[50,66]. (Figure 7)
The functional relevance of maternal vasodilation is
underscored by the association of preeclampsia and intra-
uterine growth restriction (IUGR) with a reduced plasma
volume in spite of elevated aldosterone levels, which pre-
cede the clinical onset of either disease[6,67]. A potent
vasodilatory effect on the mother is also supported by a
marked intragestational reduction of pulmonary artery
resistance in a patient with idiopathic pulmonary hyper-
tension, which coincided with elevation of the urinary
excretion of vasodilators[68].
Vasodilatory network, integrated by the five vasodilators included in this review, and their cognate interactions Figure 6
Vasodilatory network, integrated by the five vasodilators included in this review, and their cognate interac-
tions. While the majority of pathways are stimulatory, (1) ACE degrades bradykinin into inactive peptides, and diminishes its 
vasodilating effect[13], thus when (2) Ang-(1–7) competes with Ang I for ACE it indirectly potentiates bradykinin[16]. (3) Ang-
(1–7) also enhances bradykinin activity[17]. (4) The AT-2-R stimulated by Angiotensin II activates eNOS, and (5) the B2R [23-
25]. (6) The Mas-R activated by angiotensin-(1–7) stimulates the B2R[20], and (7,8) jointly with bradykinin activates 
eNOS[19](9,10). Activation of the B2R[13] and the Mas-R stimulates prostacyclin synthesis[21]. (11,12) The VEGF-R2 stimu-
lates eNOS[23] and prostacyclin production[24]. Finally, the classical vasoconstrictor AT-1-R exerts in gestation a paradoxical 
vasodilatory effect by (13,14) stimulating the synthesis of NO and prostacyclin[95,96]. Stimulatory factors = blue balloons; 
stimulatory pathways = red arrows; inhibitory pathways = red arrows interrupted by oblique line; pathways exclusive to gesta-
tion = purple arrows.
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Role of vasodilators in the local adaptation to pregnancy: 
1. Animal studies
Three observations lead us to believe that, apart from par-
ticipating in the systemic maternal hemodynamic
changes, vasodilators may play a primordial role in the
local uteroplacental adaptation to pregnancy: Firstly,
increased vasodilation is observed in the implantation
site[69,70]. Secondly, decidual edema to facilitate inva-
sion requires vasodilatory/hyperpermeability fac-
tors[71,72] (e.g. VEGF, bradykinin). And finally,
vasodilation of utero-placental arteries starts prior to tro-
phoblast invasion of the latter [73-75]. In addition, the
respective vasodilatory factors may be involved in regulat-
ing fetoplacental perfusion and in protecting the intervil-
lous space and the fetoplacental vessels from platelet
aggregation. A series of experiments in animals support
this view.
Prostanoids
During normal term pregnancy, prostanoid production
increases in the uteroplacental unit. Both spectra of pros-
tanoid activity, the vasoconstrictive and pro-aggregatory
effects of TXA2, countered by the vasodilatory and platelet
dissociating activities of prostacyclin serve to maintain a
balanced utero-placental circulation. In placenta from
salt-loaded pregnant rats TXB2 (stable metabolite of TXA2)
increases, while 6-keto-PGF1 (stable metabolite of PGI2)
decreases[76]. These experimentally induced changes in
placental prostanoids are similar to those observed in
human preeclampsia (see above); they favor vasoconstric-
tion and are consistent with increased lipid peroxidation.
Nitric oxide
The first demonstration of the presence of eNOS in
guinea-pig trophoblast was provided by Nanaev and cow-
orkers, who described extravillous trophoblast cells
immuno-positive for eNOS[77]. These extend from the
subplacenta (the guinea-pig correlate of human cell col-
umns), via the myometrium into the mesometrium; they
surround uteroplacental arteries and invade the latter,
replacing endothelial cells. This study strongly supports
the paracrine role of vasodilators on uterine arteries by
demonstrating that the lumen of utero-placental arteries
starts dilating already in those segments which are only
surrounded by serosal and adventitial eNOS positive
extravascular trophoblast cells, but have not yet been
invaded. This finding, and the fact that only the already
dilated segments were subsequently invaded by trophob-
last, challenges the concept that arteries dilate as a conse-
quence of trophoblast-mediated vessel wall destruction
(for review see Kaufmann et al. 2003). The data suggest
that NO secretion by the periarterial trophoblast consti-
Urinary excretion of angiotensin-(1–7) and active kallikrein in women in menstrual cycle and in 10 women with normotensive  pregnancies[50,56] Figure 7
Urinary excretion of angiotensin-(1–7) and active kallikrein in women in menstrual cycle and in 10 women with 
normotensive pregnancies[50,56].

9&	
8:; <:; =:; ->:; -/:; -8:; -=:> //:> 78:>
?


















&























?
@










#


!


!
1



	




@





>
/>>
8>>
<>>
=>>
->>>
-/>>
-8>>
-<>>





 


#











#!!1

Reproductive Biology and Endocrinology 2009, 7:79 http://www.rbej.com/content/7/1/79
Page 10 of 20
(page number not for citation purposes)
tutes the "pacemaker" that dilates the arteries and turns
them into vessels receptive to trophoblast penetration[1].
Also in the guinea-pig, kallikrein, the B2R, eNOS, VEGF
and its Flt-1 and KDR receptors, are expressed in the sub-
placenta, syncytial streamers, and in late pregnancy in the
periarterial and intramural trophoblast[78,79]. These data
suggest that the vasodilatory effect of NO demonstrated
by Nanaev and coworkers may be enhanced by a multifac-
torial paracrine/autocrine network.
The findings in the guinea-pig are of special importance
since this species shares with women (a) the hemomono-
chorial placenta, (b) invasion of the decidua and the uter-
oplacental arteries by extravillous trophoblast, derived
from the subplacenta, the guinea-pig analogue of the
human cell columns, and (c) remodeling of the uteropla-
cental arteries. Moreover, circulating sex steroid levels in
guinea-pigs and women follow analogous patterns during
pregnancy, and responses to progesterone antagonist
treatments are similar[80]. Because of the structural and
hormonal similarities, guinea-pigs provide the best non-
primate species for understanding the functional role of
vasodilators in pregnancy[77,81]. Several morphological
and functional homologies between the uteroplacental
units of women[82] and guinea-pigs[83,84], and the
vasodilator factors expressed in the different cellular sub-
types, are summarized in Figure 8.
Kallikrein-kinin system
In the rat, kallikrein in luminal and glandular epithelium
increases markedly in pseudopregnancy, rises further fol-
lowing intraluminal oil stimulation and in unilateral
pregnancy, thus demonstrating its dependency on hormo-
nal and mechanical stimulation [85-87]. A marked
increase is observed in the luminal and glandular epithe-
lium of the implantation node, attaining its maximum at
day 7, coinciding with the increase in uterine blood flow
and permeability. From day 14 onwards kallikrein is
absent in the placental labyrinth and trophospongium.
The B2R colocalizes with kallikrein, and is also expressed
in decidual cells, myometrial and vascular smooth mus-
cle, endothelial cells in decidua and myometrium, and in
the fetal endothelial cells of the placental labyrinth[88].
In the light of the findings of Vercruysse et al[89], what we
previously defined as retroplacental sinusoids surrounded
by cells expressing kallikrein and the B2R, correspond to
transformed uterine arteries with perivascular trophob-
lasts.
Vasodilator component of renin-angiotensin system
In the rat, Ang-(1–7) and ACE2 localize in the primary
and secondary decidual zone, and in the luminal and
glandular epithelium. At gestational day 7 Ang-(1–7) lev-
els are downregulated in the implantation zone. From day
14 onwards Ang-(1–7) and ACE2 are expressed in the lab-
yrinthine placenta, and at day 19 are increased in the uter-
ine wall and expressed in the placenta. In rats submitted
to a reduction of uterine perfusion pressure (RUPP), a
model that mimics preeclampsia, the placental expression
of Ang-(1–7) and ACE2 mRNA is decreased[90]. The
dampening of Ang-(1–7) in the implantation zone, its
later rise in uterus and the marked placental expression
suggest that the peptide is tightly regulated, feasibly to
permit the angiogenesis required by placentation, and to
enhance perfusion once the placenta is developed. The
low levels of Ang-(1–7) and ACE2 in the RUPP model
may represent an inhibition of the vasodilator arm of the
renin-angiotensin system associated with factors gener-
ated by the reduced placental blood flow (sFlt-1, TNF-,
angiotensin type 1 receptor auto-antibody) [91-93]. The
uterine and placental concentrations of Ang II are similar
to those of Ang-(1–7), but in RUPP animals Ang II pre-
dominates over Ang-(1–7). Uterine ACE mRNA increases
in RUPP, while it decreases in the placenta[90]. In the
guinea-pig Ang-(1–7) and ACE2 are expressed in the lab-
yrinthine and interlobular placenta, in syncytial stream-
ers, interstitial, perivascular and intravascular
cytotrophoblasts; in contrast to other vasodilator factors,
no expression of Ang-(1–7) and ACE2 have been detected
in the subplacenta, providing evidence of a tight regula-
tion of the peptide and its generating enzyme (Joyner,
Brosnihan, Corthorn, unpublished observations),
Surprisingly, in pregnant sheep the infusion of Ang II
evokes a decreased vascular resistance, associated with
stimulation of NO and PGI2  production[94,95]. The
ovine placenta expresses both angiotensin receptors, with
predominance of the AT1-R in early pregnancy, and simi-
lar expressions of the AT1 and the AT2-R in late preg-
nancy. The AT1-R and eNOS colocalize in the
fetoplacental endothelial cells, and the AT1-R has been
shown to mediate the Ang II increases in eNOS protein
expression and NO production[96]. In turn, NO can stim-
ulate angiogenesis and attenuate Ang II vasoconstriction.
The paradox that the potent vasoconstrictor Ang II exerts
a vasodilatory effect via eNOS and PGI2 in the uteropla-
cental unit further stresses the physiological relevance of
vasodilation in pregnancy. These responses are unique to
pregnancy, and to the endothelium of uterine arteries, as
they have not been observed in virgin sheeps and in sys-
temic arteries of pregnant ewes [97]. The important role of
the vasodilatory effects of Ang II in pregnancy is empha-
sized by the fact that these are absent in the uterine arteries
of the non-pregnant sheep and in systemic arterial seg-
ments from pregnant animals; furthermore, it is under-
lined by the catastrophic effects on fetal hemodynamics of
either converting enzyme inhibitors or by blockade of the
Ang II type 1 receptor [98-101].Reproductive Biology and Endocrinology 2009, 7:79 http://www.rbej.com/content/7/1/79
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Role of vasodilators in the local adaptation to pregnancy: 
2. Studies in human reproductive tissues
The data obtained in animal experiments are supported
by several descriptive findings and in vitro studies on
human reproductive tissues.
Prostanoids
Trophoblast cells, endothelial cells, macrophages, fibrob-
lasts, smooth muscle and decidual cell express cyclooxyge-
nases; COX-2 is co-expressed in macrophages, fibroblasts,
endothelial cells and smooth muscle cells. COX-1 mRNA
expression does not differ in placenta of preeclamptic
pregnancies, but is elevated in the placental bed, as com-
pared to normal pregnancies; while COX-2 mRNA was
unchanged. The thromboxane/prostacyclin ratio, as well
as lipid peroxides, are higher in villous cytotrophoblast,
and villous core from preeclamptic pregnancies than in
those of normal pregnancies[102]. These results, which
agree with earlier work on placental tissue[103], indicate
that the placenta, and in particular the cytotrophoblast,
may contribute to the imbalance of thromboxane and
prostacyclin observed in preeclampsia, which likely pro-
motes the coagulopathy and heightened vascular respon-
siveness so characteristic of this condition.
Schematic representation of the placenta and fetoplacental junctional zone of humans and guinea-pigs Figure 8
Schematic representation of the placenta and fetoplacental junctional zone of humans and guinea-pigs. In order 
to highlight comparable structures, all fetal tissues are colored blue and green, all maternal structures red and brown. The main 
cellular and syncytial structures of both placentas are listed together with the reported expression of the vasodilator factors 
and enzymes. Factors are underlined when present in both species; isolated factors expressed only in one of the two species 
are lateralized to the presenting species. When the whole panel of factors is described in one of the species, this is depicted by 
a blue arrow pointing to the respective structures. Note that in the human an equivalent for periarterial trophoblast is not 
known. TB = trophoblasts; CTB = cytotrophoblasts; STB = syncytiotrophoblast.
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Nitric oxide
NOS activity has been described in human trophoblast
from early placenta (first trimester), term placenta and
myometrium. In the first trimester immunohistochemis-
try demonstrates eNOS in the villous syncytiotrophoblast,
the cell columns of anchoring villi and in extravillous tro-
phoblast at the implantation site. It is conceivable that
relaxation of the vascular walls at the implantation site
may be caused by NO provided by trophoblast cells. As
described above for the guinea-pig placenta, NO and
related local vasodilators may well be involved in the
maximum dilation of uteroplacental arteries. This process
was first described and attributed to trophoblast-derived
wall destruction by Robertson and coworkers[104]. It
starts at 8 weeks of gestation[105], and thus before onset
of arterial wall decomposition by invasive trophoblast
cells[74]. Only the already dilated arteries are subse-
quently invaded by trophoblast. Lyall and cowork-
ers[106] could not find NOS expression in invasive
trophoblast in human placental bed biopsies. This nega-
tive finding was, however, contradicted by Martin and
Conrad who found immunohistochemical and in-situ-
hybridization proof for the extravillous trophoblastic
expression of eNOS[107]. Taken together, it is meanwhile
quite likely that the classical hypothesis of uteroplacental
arterial dilatation as a consequence of trophoblast-
induced wall destruction must be revised and that the
NO-induced dilatation described for the guinea-pig by
Nanaev and coworkers can be transferred also to the
human condition (for review see Kaufmann, Black, Hup-
pertz 2003)[1].
Significantly higher and undisputed activities of eNOS
were found in villous trophoblast, suggesting a relation
between number of trophoblastic cells and eNOS activ-
ity[108]. NO formation in villous syncytiotrophoblast
may importantly contribute to dilatation of underlying
fetal vasculature, and may prevent platelet aggregation
when released into the intervillous space. The role of pla-
cental NO is backed by several functional studies. In iso-
lated perfused human placental cotyledons from normal
and preeclamptic pregnancies, blockade of NO synthesis,
but not indomethacin, increases the resting fetal per-
fusion pressure; 5-hydroxytryptamine causes greater
increases in perfusion pressure in preeclamptic than in
normal placentas. In chorionic arteries and veins from
normal placentas, NO blockade enhances the pressor
effect of 5-hydroxytryptamine; in preeclamptic placentas
this effect – which is reduced by COX inhibition – is not
significantly modified[109]. These results suggest that
basal release of NO, but not of vasodilator prostanoids,
may contribute to the low resting vascular tone in normal
placentas, and to attenuate the strong vasoconstrictor
effect induced by 5-HT.
In dually perfused placental cotyledons several NO inhib-
itors (N omega-nitro-L-arginine (NOLA), hemoglobin
and methylene blue) increase fetal vessel basal perfusion
pressure and also increase the constriction induced by the
thromboxane mimetic U46619[110]. NOLA markedly
potentiates the constrictor effects of endothelin-1, angi-
otensin II, and 5-hydroxytryptamine showing that NO
contributes to maintain low basal fetal vessel impedance,
and reduces the effects of vasoconstrictors; thus reduced
NOS activity could contribute to the pathogenesis and/or
effects of preeclampsia. In contrast with the changes asso-
ciated with NO, COX inhibitors do not affect fetal vessel
basal perfusion pressure nor potentiate the effects of the
thromboxane mimetic.
In perfused segments of human umbilical artery and vein
with intact endothelium the relative release of PGI2 and
NO has been compared, utilizing the cascade bioassay.
The basal release of NO from the artery is approximately
five times greater than that of PGI2. After stimulation with
the calcium ionophore A-23187, the release of NO from
vein and artery increases five to six-fold, and is three times
greater compared with that of PGI2. NO is also more
potent in relaxing endothelium-denuded fetoplacental
vessels in vitro relative to PGI2[111]. These studies suggest
that NO is more important than PGI2 for maintenance of
low vascular tone in fetoplacental vessels.
The importance of NO is also underscored by the
improvement in the local and systemic perfusion changes
that accompany the supplementation of hypertensive
pregnant patients with L-arginine, the substrate of NOS.
Supplemented patients show reductions of arterial pres-
sure and the resistance of uterine arteries both in the short
and long term[112,113]; in the long term L-arginine sup-
plementation is also associated with improvement in
blood pressure control and NO synthesis [113-115].
These benefits pose the need to extend the preliminary
studies with L-arginine supplementation and NO donors.
The evaluation of the local expression of eNOS in preec-
lampsia has yielded discordant results. Myatt et al. com-
paring the presence and localization of eNOS and
nitrotyrosine (a marker of peroxynitrite formed by inter-
action of NO and superoxide) in placental villi from nor-
motensive pregnancies and pregnancies complicated by
preeclampsia, found that the later displays greater nitroty-
rosine immunostaining in vascular endothelium, in the
surrounding vascular smooth muscles and in villous
stroma[116]. Moreover, they found intense eNOS stain-
ing in endothelium of stem villous vessels and the small
muscular arteries of the terminal villi. Consistent with
these findings Shaamash et al. found that both placental
NOS activity and NO end-products (nitrites and nitrates)
are significantly higher in villous homogenate of preec-Reproductive Biology and Endocrinology 2009, 7:79 http://www.rbej.com/content/7/1/79
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lamptic placentae compared to those of normal preg-
nancy; in addition, the increased NOS activity and NO
production are directly related to the severity of this syn-
drome[117]. Recently, Norris et al. found that nitric oxide
metabolites (nitrites) in the uterine vein draining the pla-
centa in preeclamptic women delivered by cesarean sec-
tion are higher than in normotensive pregnancies [118].
Based on these findings, Myatt, Shaamash and Norris pos-
tulate that increased NO placental production represents
a compensatory mechanism to offset the pathologic
effects of preeclampsia.
Schiessl on the other hand, found no differences in immu-
nohistochemical expression of eNOS in the syncytiotro-
phoblast and extravillous trophoblast of placentas of
normal controls and preeclamptic mothers, although pla-
centas with IUGR show a decreased immunoreactivity and
eNOS protein content, as estimated by Western blot-
ting[119]. Work by our group demonstrates that eNOS is
similarly expressed in the syncytiotrophoblast and in the
fetal endothelium in control and preeclamptic pregnan-
cies[120], coinciding with the findings of Orange et al.,
who in this light, have excluded a possible pathogenic role
for eNOS in this disease [121]. Wang et al., found a simi-
lar nitric oxide production in placental homogenates from
preeclamptic and normal term pregnancies[122]. In addi-
tion, Conrad and Davis, measuring the conversion of
[3H]arginine to [3H]citrulline, found that NOS activity in
the villi of placentae from women with preeclampsia is
not significantly different from normal pregnancies [123].
Taking a different stance, Noris et al. have shown that the
gene expression and protein content of arginase II – an
enzyme that degrades arginine to ornithine- are higher in
preeclamptic villi than in normotensive pregnancy. More-
over, in this study the concentration of the NO precursor
L-arginine in umbilical blood and in villous tissue is lower
in preeclampsia than in normotensive pregnancy. They
postulate that the lower normal L-arginine concentration
caused by arginase II overexpression redirects eNOS
toward peroxynitrite[124].
Kallikrein-kinin system
In samples obtained from sporadic miscarriages, as well as
from early and late third trimester, kallikrein mRNA is
present in syncytiotrophoblast, cytotrophoblast, and fetal
endothelial cells of placental villi, in decidual cells, in the
basal and chorionic plate vessels, in trophoblastic cell col-
umns, in interstitial and intraarterial trophoblast cells.
Tissue kallikrein protein is present in the same cell types
with the exception of trophoblastic cell columns and the
various types of extravillous trophoblast cells[120]. In first
trimester syncytiotrophoblast the intensity of the signal is
higher than that observed in normal term placentas. The
immunoreactivity of the B2R shares the same distribution
of kallikrein mRNA, and like kallikrein, is more intense in
the first trimester as compared to term. In placenta accreta,
a condition of exaggerated invasiveness, the expression of
kallikrein is increased in syncytiotrophoblast, and that of
the B2R in the fetal endothelium and in extravillous tro-
phoblast; in contrast to normal pregnancy, kallikrein is
expressed in extravillous trophoblast. In preeclampsia, the
only observed difference is an increased B2R signal in the
extravillous trophoblast. Because of the intense mixture of
different cell types composing the different uteroplacental
zone, and the inability to separate them, the variations
within the various cells types have not been confirmed by
western blotting.
Amarnani et al. perfused isolated human placental cotyle-
dons with bradykinin at low concentrations and produced
a concentration-dependent decrease in perfusion pres-
sure, whereas higher concentrations increased perfusion
pressure[125]. The decreased perfusion pressure provoked
by low dose bradykinin is potentiated by captopril (which
blocks bradykinin degradation) and is attenuated with the
B2-receptor antagonist HOE-140 or by pretreatment with
an inhibitor of nitric oxide synthase. On the other hand, a
COX inhibitor shows no effect. The latter two results
underline the importance of the vasodilatory effect which
bradykinin has on eNOS activity, but they question the
respective effect on prostacyclin production (cf. chapter
on General Aspects of Vasodilatory Systems: Kallikrein-
Kinin System).
Vasodilator components within the renin-angiotensin system
The expression of renin in placenta, uterus and fetal mem-
branes has been reported since the late 60s [126-128]. The
functional importance of the renin-angiotensin system is
illustrated by several facts: by the severe neonatal compli-
cations observed in women treated with converting
enzyme (ACE) inhibitors[129,130]; by the association of
preeclampsia to autoantibodies to the Ang II type 1 recep-
tor, and by the association of preeclampsia to the M235T
polymorphism of the gene that codes for angiotensino-
gen[131,132]. The important role RAS plays in pregnancy
is further underlined by the fact that a preeclampsia-like
model has been generated in female mice transfected with
the human angiotensinogen gene and mated with males
transfected with the human renin gene underlines this
role[133]. The novel vasodilatory components of the
renin-angiotensin system, Ang-(1–7) and its generating
enzyme ACE2 are expressed in syncytio and cytotrophob-
last, endothelial cells, vascular smooth muscle of placen-
tal villi, interstitial and intraarterial trophoblast, in
decidual cells, and in the endothelium and smooth mus-
cle of the umbilical arteries. As for kallikrein, the immu-
noreactivity for the peptide and enzyme are greater in first
trimester samples[134]. With the exception of an
increased expression of ACE2 in umbilical arterialReproductive Biology and Endocrinology 2009, 7:79 http://www.rbej.com/content/7/1/79
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endothelium in preeclampsia, the expression of Ang-(1–
7) and ACE2 is similar in different cell types in reproduc-
tive tissues from normal term or preeclamptic pregnan-
cies. However, Ang-(1–7) does not change in the
chorionic villi of preeclamptic women, whereas Ang II is
increased; this suggests that the balance of these two bio-
logically active peptides may be shifted toward the Ang II
vasoconstrictor arm of the RAS[135]. The differences in
tissue versus circulating concentrations of the various
components of the RAS are highlighted by the fact that
Ang-(1–7) is decreased in the blood of preeclamptic
women[57].
Messenger RNAs of renin, angiotensinogen. ACE, ACE2,
NEP, AT1, AT2 and Mas receptors have been demon-
strated in placenta and placental bed[136]. Immunoreac-
tivities for angiotensinogen and AT1R are increased in
chorionic villi and decidua of preeclamptic subjects, as
compared to normal[135]. Herse et al., has found an
upregulation of decidual AT1R mRNA in preeclampsia; in
contrast, the vasodilator AT2 receptor gene expression is
present in 4% of the preeclamptic versus 60% of con-
trols[135,137].
The assumption of an interaction between bradykinin and
the renin-angiotensin system is supported by the observa-
tion that Ang I at concentrations present in the fetal circu-
lation, but not Ang II, potentiates the vasodilator effect of
bradykinin in the fetoplacental vessels[125]. This
enhancement may relate to Ang-(1–7) which also derives
from Ang I.
VEGF
Is expressed in the non-pregnant endometrium, and its
transmembranous receptors VEGFR-1 (Flt-1) and VEGFR-
2 (KDR), as well as s-VEGFR-1 (sFlt1-1), display a cyclic
regulation throughout the menstrual cycle[138,139].
VEGF seems to be crucial for uterine receptivity, as its
mRNA expression is detected in the blastocyst; its transla-
tion may enable the implanting ovum to induce angio-
genesis – and probably hyperpermeability – at the
implantation site by binding to the ligand of endometrial
receptors[140]. Later in pregnancy VEGF is expressed
mainly in villous cytotrophoblasts[141], in syncytiotro-
phoblast[142], the invading front of trophoblastic cell
columns, extravillous[143] and in endovascular cytotro-
phoblast. VEGF-receptor binding stimulates the cytotro-
phoblastic expression of integrin 1, a molecule of the
invasive repertoire that interacts with the maternal extra-
cellular matrix and is characteristic for the invasive subset
of extravillous trophoblast[144]. At early gestational
stages, immunoreactivities of VEGF-C, VEGF-R1 and
VEGF-R2 in intramural extravillous trophoblast (EVT) are
reduced as compared to those in mononuclear interstitial
and intraarterial EVT. The intramural EVT expression for
VEGF-C increases along pregnancy, while a reduction in
VEGF-R1 and VEGF-R2 by intraarterial EVT was
observed[145]. VEGF in perivascular trophoblast could
through its vasodilator effect prime the uterine arteries for
invasion, as suggested for NO[77], thus enhancing their
high blood flow.
As already mentioned earlier, VEGF exerts its vasodilatory
effects via activation of eNOS and of prostacyclin synthe-
sis. This has been shown also for the human placenta:
Dual perfusion of human term placental lobules with
VEGF at physiological concentrations exerts a potent
vasodilation of the fetoplacental vasculature, partially
mediated by VEGFR-2, via NO as a second messenger[61].
Conclusion
The data listed above demonstrate that at least five differ-
ent vasodilator systems are involved in the control of uter-
oplacental and fetoplacental hemodynamics throughout
pregnancy, the vasodilator component of the renin-angi-
otensin system, the kallikrein-kinin system, prostacyclin,
nitric oxide and VEGF. Several decades after Walsh pro-
posed a balance between the vasoconstrictor thrombox-
ane and the vasodilating prostacyclin to sustain normal
pregnancy, the number of players in this delicate balance
has expanded; furthermore the local balance has to be
extended to that of maternal hemodynamics, as proposed
by Wallenburg [146-148] (Figure 9). The multiplicity of
components that integrate the vasodilator surge of preg-
nancy probably exerts compensatory functions and pro-
vides finely tuned relay systems in the changes in the
hormonal milieu of pregnancy, and in the oxygen tension
of the intervillous space. Moreover, there is increasing evi-
dence that the various vasodilator systems intensely inter-
act, partly only modulating each other, partly even using
parts of the other systems to exert their own function, e.g.
VEGF stimulating eNOS activity and prostacyclin produc-
tion. Some of these interactions seem to be specific for
pregnancy, e.g. upregulation of prostacyclin by Ang II.
There are still uncertainties, contradictions and data,
e.g.eNOS/NO, that seemingly do not fit into the picture of
a functioning vasodilator network. This is mainly due to
the fact that a more detailed analysis of the data is ham-
pered by various problems: The environment, diet and
genetics of the individuals studied. The estimation of
activities of the involved factors, often based on semi-
quantification of immunoreactivities, Northern and West-
ern blotting, must be generally interpreted with caution.
The impossibility of early sampling in pregnancies that
can be characterized as normal or preeclamptic at term,
the restricted availability of normal human material from
the second trimester, and the difficulties inherent to pla-
cental bed biopsies even at term are further obstacles
when attempting to interpret longitudinal profiles of theReproductive Biology and Endocrinology 2009, 7:79 http://www.rbej.com/content/7/1/79
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Balance between immunological, morphological and vasoactive factors that determine an adequate or a defective adaptation to  pregnancy, both at the level of the uteroplacental unit and the mother Figure 9
Balance between immunological, morphological and vasoactive factors that determine an adequate or a 
defective adaptation to pregnancy, both at the level of the uteroplacental unit and the mother. For the purpose 
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various players. By contrast their circulating levels and uri-
nary excretion data are reliable, but difficult to interpret
because of the huge variety of potential sources of secre-
tion/excretion. Finally, having in mind the complexity of
the vasodilator network, in vitro studies on human tissues
and experimental manipulation of single factors in ani-
mal studies do not only bear the danger that data may be
difficult to translate to the human; moreover, it would not
be surprising if experimental alterations induced in one
system are compensated by the interacting with other
players of the network. The same, of course, is valid when
studying serum or urine data from patients from preg-
nancy disorders with or without treatment.
In spite of these caveats, the data provided by many
groups suggest that preeclampsia is a typical example of a
disorder in which the balance between vasoconstrictor
and vasodilator systems, and possibly even the balance
within the vasodilator network, is disturbed (Figure 8).
This by no means implies that a deranged vasoconstrictor/
vasodilator balance is sufficient to explain the pathogene-
sis of preeclampsia. It is clear that cell biological interac-
tions between invading trophoblast and uteroplacental
arterial walls, general problems of the uterine or even sys-
temic vasculature of the mother, as well as the immuno-
logical interaction between mother and her semiallograft,
provide alternative underlying pathogenetic mechanisms.
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